Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today initial data from its ongoing Phase 1/ 2 study with ALN-GO1, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1. Initial clinical results were presented today during an oral presentation at the 17th...
BASEL- Novartis announced that the US Food and Drug Administration or FDA has granted three simultaneous approvals for the expanded use of Ilaris to treat three rare and distinct types of Periodic Fever Syndromes: Tumor Necrosis Factor-Associated Periodic Syndrome, Hyperimmunoglobulin D Syndrome/ Mevalonate Kinase Deficiency and Familial...
-Sunesis Pharmaceuticals, Inc. today announced that the Company will present at two upcoming investor conferences:. 2016 Wells Fargo Healthcare ConferenceWednesday, September 7th at 2:20 PM Eastern TimeThe Westin Boston Waterfront, Boston. Rodman& Renshaw 18th Annual Global Investment ConferenceTuesday, September 13th at 2:10 PM Eastern TimeLotte N
-Labeling update includes clinical data on use of Rexulti in adult patients with schizophrenia in the maintenance phase of treatment. Valby, Denmark and Princeton, New Jersey, 23 September 2016- H. Lundbeck A/S and Otsuka Pharmaceutical Development& Commercialization, Inc. announced today that the US Food and Drug Administration approved the labeli
AbbVie, a global biopharmaceutical company, today announced new data showing high response rates with just eight weeks of VIEKIRAX + EXVIERA treatment. In the Phase 3 b GARNET study, 98 percent of previously untreated patients with genotype 1 b chronic hepatitis C virus infection without cirrhosis achieved sustained virologic response rates
By a News Reporter-Staff News Editor at Health& Medicine Week Abeona Therapeutics Inc. EB-101 has demonstrated promising clinical efficacy in patients for the treatment of recessive dystrophic epidermolysis bullosa Phase 1/ 2 clinical trial enrolled with data indicating significant improvements in wound healing and gene expression 12 months...
September 21 st, 2016, Abeona announced the exclusive worldwide license of a next generation gene therapy AAV capsid portfolio from University of North Carolina at Chapel Hill September 8 th, 2016, Abeona Enrolls 5 th Patient in Phase 1/ 2 Gene Therapy Clinical Trial for Epidermolysis Bullosa August 29, 2016, Abeona completes Enrollment of Low-Dose
Achillion Pharmaceuticals, Inc. announced that updated interim results were presented today in an ePoster describing a phase 2 study being conducted by Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies at the European Association for the Study of the Liver Special Conference in Paris, France. These results, updated to include exp
Allergan plc today announced the company has received approval from the U.S. Food and Drug Administration to market NATRELLE INSPIRA Cohesive breast implants, offering women undergoing reconstruction, augmentation or revision surgery a new breast shaping option that combines a high gel fill ratio and Allergan's highly cohesive gel 1,2 for a...
-Antares Pharma, Inc. today announced safety results from the dose-blinded, multiple-dose, concentration-controlled, 26- week phase 3 study of QuickShot Testosterone administered subcutaneously once each week to adult males with hypogonadism. The study, QST-15-005, included a screening phase, a titration phase and a treatment phase for evaluation o
Catabasis Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, today announced the pricing of an underwritten offering of 2,500,000 shares of its common stock at a price of $4.00 per share. Additional details regarding the offering will be included in a Form 8- K filed by Catabasis with the Securities and Exchange Commission.
By a News Reporter-Staff News Editor at Genomics& Genetics Weekly Men in the United States can now have easier access to fast and accurate testing for a potentially dangerous sexually transmitted infection, thanks to expanded claims allowed by the Food and Drug Administration for the Xpert TV assay by Cepheid, a sensitive urine-based test for Tri
NEW YORK, Sept. 23, 2016/ PRNewswire-USNewswire/ Medicinal chemist and pharmacologist Daniel Martin Watterson, PhD, has been named the second annual winner of the Alzheimer's Drug Discovery Foundation's Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Discovery. Dr. Watterson is the John G. Searle Professor of Molecular Biology and Bioch
Enanta Pharmaceuticals, Inc.,, a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new data showing high response rates with just eight weeks of VIEKIRAX + EXVIERA treatment. In AbbVie s Phase 3 b GARNET study, 98 percent of previously u
The Phase 1 trial is being conducted in Australia and is targeted to enroll approximately 40 subjects. Our elemental reducing agents have demonstrated compelling activity in a number of animal studies, including models of cardiac reperfusion, radiation injury and organ transplantation, "said Stephen A. Hill, M.D., Chief Executive Officer of Faraday
WASHINGTON Federal regulators on Friday approved the first alternative version of the second-best selling drug in the world, Humira, the blockbuster injection used to treat rheumatoid arthritis and other inflammatory diseases.
FIT BIOTECH OY Company release September 23, 2016 at 16:40 EET Tekes issues a partial decision on the company's rectification request related to Tekes's claim to capital loan related to the FIT Biotech HIV vaccine project in 2009-2010 According to FIT Biotech's company release of June 22,2016, Tekes had reclaimed part of FIT Biotech's Development o
By a News Reporter-Staff News Editor at Drug Week Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced that it has appointed Liat Hayardeny, Ph.D., MBA, as Chief Scientific Officer, effective as of September 7, 2016.
GlaxoSmithKline Plc promoted Emma Walmsley to be its new chief executive officer and succeed Andrew Witty when he retires, singling out the UK`s largest drugmaker as the only major global pharmaceutical company led by a woman. She will join the board on Jan 1 and take the helm of the London- based company on March 31, Glaxo said in a statement on T
LONDON- GlaxoSmithKline PLC on Friday said it has submitted a biologics licence application to the US Food& Drug Administration covering sirukumab in rheumatoid arthritis. The drug giant said the application has been filed by Janssen Biotech Inc, seeking approval of a subcutaneous formulation of sirukumab for the treatment of adult patients with...
Clinical Trial Imaging By Technology Market For Biotech Companies, Pharmaceuticals, Research Center, Hospitals, And Other End-Users: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 2021 Sarasota, FL 09/23/2016 The report covers forecast and analysis for the clinical trial imaging
Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions. Novartis International AG/ Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions. Basel, September 23, 2016- Novartis announced today that the US Food and Drug
"We are pleased to add Dr. Newman to our board of directors," said Ted Schroeder, chief executive officer of Zavante. Dr. Newman recently completed a five-year term as a member of the Labor, Education and Healthcare Council of the Federal Reserve Bank of Atlanta, and also served as a member of the Boards of Directors of Optimer Pharmaceuticals, Inc
Janssen Biotech, Inc. announced today the submission of a Biologics License Application to the United States Food and Drug Administration seeking approval of sirukumab for the treatment of adult patients with moderately to severely active rheumatoid arthritis. We are committed to deepening our understanding of rheumatoid arthritis with the goal
-NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system disorders, today reported human factors data from a usability study focused on the interactions between Parkinsons disease patients and the mini-pump device used to administer ND0612, the Companys continuous, subcutaneously delivered...